Aspirin / butalbital / caffeine Alternatives Compared
Aspirin / butalbital / caffeine | Ubrelvy | Sumatriptan |
|
---|
Aspirin / butalbital / caffeine | Ubrelvy (ubrogepant) | Sumatriptan |
|
|||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Prescription only
Prescribed for Migraine, Headache, Pain. aspirin / butalbital / caffeine may also be used for purposes not listed in this medication guide. |
Prescription only
Ubrelvy may be used to treat acute migraine attacks in adults and works by blocking the effects of a protein, called CGRP that is thought to play a role in migraine attacks by causing pain, dilation... View more |
Prescription only
Sumatriptan may be used to quickly relieve the symptoms of a migraine but may not be suitable for everyone including those with pre-existing cardiovascular conditions. Prescribed for Cluster... View more |
Related suggestions |
|||||||||||||||||||||||
More about Aspirin / butalbital / caffeine | More about Ubrelvy (ubrogepant) | More about Sumatriptan | ||||||||||||||||||||||||
Ratings & Reviews | ||||||||||||||||||||||||||
Aspirin / butalbital / caffeine has an average rating of 8.9 out of 10 from a total of 122 ratings on Drugs.com. 88% of reviewers reported a positive effect, while 6% reported a negative effect. |
Ubrelvy has an average rating of 6.1 out of 10 from a total of 237 ratings on Drugs.com. 55% of reviewers reported a positive effect, while 39% reported a negative effect. |
Sumatriptan has an average rating of 7.7 out of 10 from a total of 544 ratings on Drugs.com. 71% of reviewers reported a positive effect, while 17% reported a negative effect. |
||||||||||||||||||||||||
Drug Class | ||||||||||||||||||||||||||
Side Effects | ||||||||||||||||||||||||||
See also: aspirin / butalbital / caffeine side effects in more detail. |
See also: Ubrelvy side effects in more detail. |
See also: sumatriptan side effects in more detail. |
||||||||||||||||||||||||
Generic Availability | ||||||||||||||||||||||||||
Lower cost generic |
Lower cost generic |
|||||||||||||||||||||||||
Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
|
View all Ubrelvy prices |
View all sumatriptan prices |
||||||||||||||||||||||||
Dosage Form(s) Available | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
Brand Names | ||||||||||||||||||||||||||
Farbital, Fiorinal, Fiormor, Fiortal, Fortabs |
N/A |
Imitrex, Imitrex Nasal, Imitrex Statdose, Onzetra Xsail, Tosymra, Zembrace SymTouch | ||||||||||||||||||||||||
Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | ||||||||||||||||||||||||||
35 hours |
7 hours |
6 hours |
||||||||||||||||||||||||
CSA Schedule ** View glossary of terms | ||||||||||||||||||||||||||
Moderate abuse potential
Has a potential for abuse less than those in schedules 1 and 2. Has a currently accepted medical use in treatment in the United States. Abuse may lead to moderate or low physical dependence or high psychological dependence. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
Pregnancy Category | ||||||||||||||||||||||||||
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
||||||||||||||||||||||||
Drug Interactions | ||||||||||||||||||||||||||
A total of 853 drugs are known to interact with aspirin / butalbital / caffeine:
|
A total of 218 drugs are known to interact with Ubrelvy:
|
A total of 99 drugs are known to interact with sumatriptan:
|
||||||||||||||||||||||||
Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||
Disease Interactions | ||||||||||||||||||||||||||
|
||||||||||||||||||||||||||
First Approval Date | ||||||||||||||||||||||||||
May 04, 1976 |
December 23, 2019 |
January 28, 2016 |
||||||||||||||||||||||||
WADA Class View World Anti-Doping Agency classifications. | ||||||||||||||||||||||||||
N/A |
N/A |
N/A |
||||||||||||||||||||||||
More Information | ||||||||||||||||||||||||||
Patient resources | ||||||||||||||||||||||||||
Professional Resources | ||||||||||||||||||||||||||
Related Treatment Guide | ||||||||||||||||||||||||||
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.